An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Cork, M. J. [1 ]
Thaci, D. [2 ]
Davis, J. D. [3 ]
Zhang, Q. [3 ]
Akinlade, B. [3 ]
Graham, N. M. H. [3 ]
Pirozzi, G. [4 ]
Bansal, A. [3 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Univ Hosp Schleswig Holstein, Lubeck, Germany
[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Sanofi, Bridgewater, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P94
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [21] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [22] Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
    Mareschal, Adrien
    Puzenat, Eve
    Aubin, Francois
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 (01)
  • [23] The effect of dupilumab on the pharmacokinetics of cytochrome P450 substrates in adult patients with moderate-to-severe atopic dermatitis: an open label phase 1 trial
    Davis, J. D.
    Bansal, A.
    Hassman, D.
    Akinlade, B.
    Li, M.
    Li, Z.
    Swanson, B.
    Hamilton, J.
    Dicioccio, A. T.
    ALLERGY, 2017, 72 : 604 - 605
  • [24] Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
    Michael J. Cork
    Diamant Thaçi
    Lawrence F. Eichenfield
    Peter D. Arkwright
    Zhen Chen
    Ryan B. Thomas
    Matthew P. Kosloski
    Ariane Dubost-Brama
    Randy Prescilla
    Ashish Bansal
    Noah A. Levit
    Dermatology and Therapy, 2023, 13 : 2697 - 2719
  • [25] Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
    Zhao, Yan
    Li, Jing-Yi
    Yang, Bin
    Ding, Yang-Feng
    Wu, Li-Ming
    Zhang, Li-Tao
    Wang, Jin-Yan
    Lu, Qian-Jin
    Zhang, Chun-Lei
    Zhang, Fu-Ren
    Zhu, Xiao-Hong
    Li, Yu-Mei
    Tao, Xiao-Hua
    Diao, Qing-Chun
    Li, Lin-Feng
    Lu, Jian-Yun
    Man, Xiao-Yong
    Li, Fu-Qiu
    Xia, Xiu-Juan
    Song, Jiao-Ran
    Jia, Ying-Min
    Zhang, Li-Bo
    Chen, Bo
    Zhang, Jian-Zhong
    BIODRUGS, 2024, 38 (05) : 681 - 689
  • [26] Open-label trial of dupilumab for adolescents with atopic dermatitis
    Ingram, John
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : IX - IX
  • [27] Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial
    Beck, Lisa
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Take-shi
    Galus, Ryszard
    Xiao, Jing
    Avetisova, Elena
    Du-bost-Brama, Ariane
    Shabbir, Arsalan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB5 - AB5
  • [28] Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension trial up to 172 weeks
    Beck, L.
    Deleuran, M.
    Blauvelt, A.
    Thyssen, J.
    Bissonnette, R.
    de Bruin-Weller, M.
    Chen, Z.
    Levit, N.
    Rodriguez Marco, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 11 - 12
  • [29] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [30] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    JAMA DERMATOLOGY, 2021, 157 (09) : 1047 - 1055
12345